Biocon Limited reported a consolidated total income of Rs 4,569 crore in Q4FY26, up 10% year-on-year on an adjusted basis, while EBITDA rose 29% to Rs 1,073 crore and net profit before exceptional items climbed 64% to Rs 179 crore. For the full year FY26, total income stood at Rs 17,270 crore, EBITDA at Rs 3,798 crore, and net profit before exceptional items at Rs 436 crore.
The company said operating revenue for Q4FY26 was Rs 4,517 crore, with an EBITDA margin of 23%, while FY26 operating revenue reached Rs 16,927 crore and EBITDA margin was 22%. Biocon said the results reflected the impact of integration across its biosimilars and generics businesses, along with improved operating leverage and product mix.
Among business segments, biosimilars remained the biggest growth driver, contributing Rs 2,756 crore in Q4FY26 revenue and Rs 10,431 crore for FY26. Generics posted Rs 847 crore in quarterly revenue and Rs 3,168 crore for the full year, while Syngene’s research services business reported Rs 1,037 crore in Q4FY26 and Rs 3,739 crore in FY26.
Kiran Mazumdar-Shaw, Executive Chairperson, said Biocon closed FY26 on a strong note despite a complex geopolitical environment and highlighted margin expansion and the creation of a unified biopharma entity. Shreehas Tambe, CEO & Managing Director, said FY26 was a pivotal year marked by the successful integration of the biosimilars and generics businesses, while Peter Bains said Syngene’s performance was in line with revised guidance.
The board recommended a final dividend of Re 0.50 per share for FY26. The company also announced board and management updates, including new independent director appointments effective August 1, 2026, and noted that Syngene and Biocon were recognized in sustainability rankings during the year.
